-1.03%
11.58%
-12.76%
-21.33%
-25.14%
-59.82%
-70.38%
AI Spotlight on BAYN
Company Description
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide.It operates through Pharmaceuticals, Consumer Health, and Crop Science segments.The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy.
The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough.The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture.This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing.
The company has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc.for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases.It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers.
Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.
Market Data
| Last Price | 21.64 |
| Change Percentage | -1.03% |
| Open | 21.94 |
| Previous Close | 21.86 |
| Market Cap ( Millions) | 21255 |
| Volume | 1562632 |
| Year High | 31.03 |
| Year Low | 18.41 |
| M A 50 | 19.84 |
| M A 200 | 25.16 |
Financial Ratios
| FCF Yield | 20.77% |
| Dividend Yield | 0.51% |
| ROE | -2.61% |
| Debt / Equity | 0.00% |
| Net Debt / EBIDTA | -43.90% |
| Price To Book | 0.7 |
| Price Earnings Ratio | -24.15 |
| Price To FCF | 4.82 |
| Price To sales | 0.45 |
| EV / EBITDA | 1.58 |
News
- Jan -24 - Agtech Seedlings: CH4 Global to expand methane-reducing cattle feed with Mitsubishi
- Jan -15 - Here’s Why Bayer Aktiengesellschaft (BAYRY) Declined in Q4
- Jan -14 - Jury orders Bayer to pay $100 million over PCBs in Washington school
- Jan -10 - Agtech seedlings: Bayer, European refinery to scale US biofuel production
- Jan -03 - Bayer Secures End of Roundup Weedkiller Litigation in Australia
- Jan -03 - Bayer: Federal Court Brings an End to Roundup™ Litigation in Australia
- Dec -24 - A year after Bayer got rid of bosses and asked staff to self-organize, its CEO says attrition has fallen
- Dec -17 - Bayer’s Eye Drug Shows Positive Results in Late-Stage Trial
- Dec -03 - FDA Accepts Cytokinetics' Application for Cardiovascular Drug
- Nov -22 - FDA Accepts Bayer's Application for Label Expansion of Nubeqa
- Nov -20 - Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan
- Nov -19 - Bayer acquires rights to Cytokinetics' heart drug in Japan
- Nov -15 - Pharma Stock Roundup: AZN, BAYRY's Earnings, ABBV's Pipeline Setback
- Nov -15 - Agtech seedlings: Bayer gets into the AI business with Microsoft
- Nov -15 - Bayer’s Worst Week in a Year Puts Scale of CEO Task Into Context
- Nov -15 - Bayer Third Quarter 2024 Earnings: Misses Expectations
- Nov -13 - Bayer AG (BAYRY) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst Challenges
- Nov -13 - Bayer urges investor patience as weak agricultural market drags earnings
- Nov -12 - Bayer Q3 Earnings Miss Estimates, Nubeqa, Kerendia Boost Sales
- Nov -12 - Stocks to Watch Tuesday: Shopify, Honeywell, Home Depot, Tyson Foods
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Crop Science
Expected Growth : 1.2 %
What the company do ?
Crop Science from Bayer Aktiengesellschaft is a leading agriculture company providing innovative crop protection, seeds, and digital farming solutions to improve agricultural productivity and sustainability.
Why we expect these perspectives ?
Bayer's Crop Science segment growth is driven by increasing global demand for sustainable agriculture, adoption of digital farming practices, and expansion in emerging markets. The company's strong R&D pipeline, strategic partnerships, and focus on climate-resilient crop solutions also contribute to its 1.2% growth.
Segment n°2 -> Pharmaceuticals
Expected Growth : 0.8 %
What the company do ?
Pharmaceuticals from Bayer Aktiengesellschaft refers to the company's division that develops and markets prescription medications, including cardiovascular, oncology, and ophthalmology treatments.
Why we expect these perspectives ?
Bayer's pharmaceutical segment growth is driven by its strong pipeline of innovative medicines, increasing demand for chronic disease treatments, and strategic acquisitions. The company's focus on research and development, particularly in oncology and cardiovascular disease, has led to the launch of new products, contributing to the 0.8% growth rate.
Segment n°3 -> Consumer Health
Expected Growth : 1.1 %
What the company do ?
Consumer Health from Bayer Aktiengesellschaft is a segment that develops and markets non-prescription medications and dietary supplements for self-care.
Why we expect these perspectives ?
Bayer's Consumer Health segment growth of 1.1% is driven by increasing demand for self-care and prevention, expansion in emerging markets, and a strong portfolio of brands such as Aspirin, Aleve, and Claritin. Additionally, the segment benefits from a growing trend towards healthy living and wellness, as well as strategic investments in digital marketing and e-commerce capabilities.
Segment n°4 -> All Other
Expected Growth : 0.9 %
What the company do ?
All Other from Bayer Aktiengesellschaft refers to the remaining business segments of Bayer, excluding Pharmaceuticals, Consumer Health, and Crop Science.
Why we expect these perspectives ?
Bayer's All Other segment growth of 0.9% is driven by increasing demand for its Animal Health products, particularly in emerging markets, and the expansion of its Consumer Health business through strategic partnerships and product launches, partially offset by declining sales in its Covestro spin-off.
Segment n°5 -> Enabling Functions and Consolidation
Expected Growth : 0.7 %
What the company do ?
Enabling Functions and Consolidation from Bayer Aktiengesellschaft refers to the company's support functions, such as HR, IT, and Finance, that enable business operations and consolidate financial results.
Why we expect these perspectives ?
Bayer's Enabling Functions and Consolidation segment growth of 0.7% is driven by operational efficiencies, cost savings initiatives, and strategic investments in digitalization and process optimization. Additionally, the company's focus on innovation and R&D, as well as its efforts to streamline its organizational structure, contribute to this growth.
Bayer Aktiengesellschaft Products
| Product Range | What is it ? |
|---|---|
| Aspirin | A pain reliever and antipyretic medication |
| Xarelto | An oral anticoagulant medication |
| Xofigo | A radiopharmaceutical for the treatment of prostate cancer |
| Kogenate | A recombinant factor VIII for the treatment of hemophilia A |
| Crop Science Products | A range of crop protection products, seeds, and traits |
| Confidor | An insecticide for controlling pests in crops |
| Larvin | A biological insecticide for controlling pests in crops |
| Advantix | A topical insecticide and acaricide for dogs |
| Drontal | An anthelmintic for the treatment of parasitic infections in animals |
Bayer Aktiengesellschaft's Porter Forces
Threat Of Substitutes
Bayer Aktiengesellschaft operates in a highly competitive industry, and there are many substitutes available for its products. However, the company's strong brand recognition and customer loyalty mitigate the threat of substitutes to some extent.
Bargaining Power Of Customers
Bayer Aktiengesellschaft's customers are largely fragmented and lack the bargaining power to negotiate prices or terms. The company's strong brand recognition and customer loyalty also reduce the bargaining power of customers.
Bargaining Power Of Suppliers
Bayer Aktiengesellschaft relies on a diverse range of suppliers for its raw materials and services. While some suppliers may have bargaining power, the company's scale and diversification of suppliers mitigate this risk.
Threat Of New Entrants
The pharmaceutical and life sciences industry has high barriers to entry, including significant research and development costs, regulatory hurdles, and the need for specialized expertise. This limits the threat of new entrants.
Intensity Of Rivalry
The pharmaceutical and life sciences industry is highly competitive, with many established players competing for market share. Bayer Aktiengesellschaft faces intense competition from rivals such as Pfizer, Novartis, and Roche.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 57.11% |
| Debt Cost | 3.95% |
| Equity Weight | 42.89% |
| Equity Cost | 8.78% |
| WACC | 6.02% |
| Leverage | 133.16% |
Bayer Aktiengesellschaft : Quality Control
Bayer Aktiengesellschaft passed 1 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| AZN.L | AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, … |
| SAN.PA | Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, … |
| GSK.L | GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the … |
| ROG.SW | Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products … |
| NOVN.SW | Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Novartis
A-Score
1-Year Total Return ->
🥈
Sanofi
A-Score
1-Year Total Return ->
🥉
Roche
A-Score
1-Year Total Return ->
4
GSK
A-Score
1-Year Total Return ->
5
AstraZeneca
A-Score
1-Year Total Return ->
6
